<DOC>
	<DOCNO>NCT00009789</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . PURPOSE : Phase I trial study effectiveness specialize high-dose radiation therapy treat patient stage I non-small cell lung cancer lung dysfunction .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerated course accelerate 3-dimensional conformal radiotherapy patient stage I non-small cell lung cancer pulmonary dysfunction . - Determine short-term long-term toxicity regimen patient . - Determine local tumor control , failure-free survival , overall survival patient treat regimen . - Determine effect radiotherapy dose volume relationships pre-treatment pulmonary function study incidence pulmonary toxicity patient . OUTLINE : This dose-escalation , multicenter study . Patients receive accelerate 3-dimensional ( 3-D ) conformal radiotherapy daily 5 day week 3.5-6 week . Cohorts 8 patient receive escalate fraction accelerate 3-D conformal radiotherapy maximum tolerate course determine . The maximum tolerated course define course 2 patient develop least grade 3 dose-limiting toxicity 1 patient develops least grade 4 dose-limiting toxicity . Patients follow 3 week , 6 week , 3 month , every 3 month 2 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage I ( T12 , N0 ) nonsmall cell lung cancer ( NSCLC ) Squamous cell carcinoma Basaloid carcinoma Adenocarcinoma Bronchoalveolar carcinoma Adenosquamous carcinoma Large cell carcinoma Large cell neuroendocrine carcinoma Giant cell carcinoma Sarcomatoid carcinoma Nonsmall cell carcinoma otherwise specify Tridimensionally measurable solitary parenchymal lung lesion great 4 cm diameter chest CT scan ( lung window ) No metastatic disease hilar mediastinal lymphadenopathy Must mediastinoscopy* ( anterior , cervical , ) mediastinal lymph node great 1.0 cm diameter chest CT scan No positive lymph node mediastinoscopy* NOTE : *Patients may positronemission tomography lieu mediastinoscopy provide fludeoxyglucose F 18 uptake mediastinum hilum Poor surgical risk , define 1 following : High risk due nonpulmonary reason , renal failure , cardiac failure , hepatic dysfunction deem thoracic surgeon unsuitable lobectomy Pulmonary dysfunction indicate one following : FEV_1 le 40 % predict DLCO le 50 % predict Oxygen dependent Chronic PaCO_2 great 45 mm Hg VO_2 le 15 mL/kg/min PATIENT CHARACTERISTICS : Age : 18 Performance status : 02 Other : Not pregnant nursing Fertile patient must use effective contraception No weight loss 10 % within past 6 month No active ( less 30 % risk relapse completion prior therapy ) malignancy except nonmelanoma skin cancer Chemotherapy : No prior chemotherapy NSCLC Radiotherapy : No prior chest radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>